Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.80 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.73 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.67 |
| ▸ | FAAH | O00519 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20648099 | 1.00 | TRPV1 (0.80) | TRPV1MTNR1AMTNR1BFAAHPTGS2 | |
| SCHEMBL31036268 | 0.95 | MTNR1A (0.72) | TRPV1MTNR1AMTNR1BFAAHPTGS2 | |
| SCHEMBL23630276 | 0.89 | TRPV1 (1.00) | TRPV1MTNR1AMTNR1BFAAHPTGS2 | |
| SCHEMBL1746356 | 0.89 | TRPV1 (1.00) | TRPV1MTNR1AMTNR1BFAAHPTGS2 | |
| SCHEMBL3815737 | 0.89 | TRPV1 (1.00) | TRPV1MTNR1AMTNR1BFAAHPTGS2 | |
| SCHEMBL23630266 | 0.89 | TRPV1 (1.00) | TRPV1MTNR1AMTNR1BFAAHPTGS2 | |
| SCHEMBL23643317 | 0.89 | TRPV1 (1.00) | TRPV1MTNR1AMTNR1BFAAHPTGS2 | |
| SCHEMBL23630280 | 0.89 | TRPV1 (1.00) | TRPV1MTNR1AMTNR1BFAAHPTGS2 | |
| SCHEMBL23630267 | 0.89 | TRPV1 (1.00) | TRPV1MTNR1AMTNR1BFAAHPTGS2 | |
| SCHEMBL23630268 | 0.89 | TRPV1 (1.00) | TRPV1MTNR1AMTNR1BFAAHPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10583119-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| EP-2282735-B1 | PP2A MODULATORS FOR TREATING ALZHEIMER, PARKINSON, DIABETES | SIGNUM BIOSCIENCES INC (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2282735-B1 | PP2A MODULATORS FOR TREATING ALZHEIMER, PARKINSON, DIABETES | SIGNUM BIOSCIENCES INC (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2282735-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | Signum Biosciences, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009132051-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009132051-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | PPP2CA, PPP4C, PPP6C | TRPV1 4687/4885MTNR1A 1889/4885MTNR1B 2090/4885 |
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | PPP2CA, PPP4C, PPP6C | TRPV1 4687/4885MTNR1A 1889/4885MTNR1B 2090/4885 |
| US-10583119-B2 | Compounds, compositions and methods for making the same | PPP2CA, PPP4C, PPP6C | TRPV1 4687/4885MTNR1A 1889/4885MTNR1B 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.